Literature DB >> 12354547

Immunohistochemical characterization of lymphosarcoma in two alpacas (Lama pacos).

S Hemsley1, G Bailey, P Canfield.   

Abstract

Species cross-reactive anti-peptide antibodies were assessed in formalin-fixed tissue for use in immunophenotyping of lymphosarcoma in two alpacas. Diagnosis of lymphosarcoma was made by routine histopathological examination. Primary antibodies used for immunophenotyping were anti-human CD3 and anti-human CD5 for T cells; and anti-human CD79a and anti-human CD79b for B cells/plasma cells. In one case, most of the neoplastic cells were labelled with both anti-CD3 and anti-CD79b, and smaller numbers were labelled with anti-CD79a. The other case was classified as a B-cell tumour on the basis of labelling of the majority of neoplastic cells with anti-CD79b and anti-CD79a. This is the first recorded attempt at immunophenotyping lymphosarcoma in alpacas and, to our knowledge, the first record of presumptive co-expression of T- and B-cell-associated molecules in lymphosarcoma in the veterinary literature.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12354547     DOI: 10.1053/jcpa.2002.0555

Source DB:  PubMed          Journal:  J Comp Pathol        ISSN: 0021-9975            Impact factor:   1.311


  3 in total

1.  Resident lymphocytes in the epidermis and adnexal epithelia of normal dorsolateral thorax of alpacas.

Authors:  Mitzi D Clark; Jeanine Peters-Kennedy; Danny W Scott
Journal:  Can J Vet Res       Date:  2013-01       Impact factor: 1.310

2.  Clinical, ultrasonographic, and laboratory findings in 12 llamas and 12 alpacas with malignant round cell tumors.

Authors:  Jeanne M Martin; Beth A Valentine; Christopher K Cebra
Journal:  Can Vet J       Date:  2010-12       Impact factor: 1.008

3.  Bovine leukemia virus infection in a juvenile alpaca with multicentric lymphoma.

Authors:  Laura C Lee; William K Scarratt; Gertrude C Buehring; Geoffrey K Saunders
Journal:  Can Vet J       Date:  2012-03       Impact factor: 1.008

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.